Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Outlook Therapeutics reports topline results from Phase 2 wet AMD trial

Outlook Therapeutics (NASDAQ:OTLK) reported topline results from its Phase 2 NORSE 1 trial evaluating ONS-5010 for the treatment of wet age-related macular degeneration (AMD). The study, whose primary endpoint is the...

August 26, 2020

Executive Moves

Perimeter Medical Imaging names Aaron Davidson to its board

Aaron Davidson Perimeter Medical Imaging (TSXV:PINK) appointed Aaron Davidson, currently CFO and SVP of corporate development at Profound Medical (TSX-V:PRN; OTCQX:PRFMF), to its board of directors. “[Mr...

August 26, 2020

Developments

Ovid Therapeutics soticlestat meets primary endpoint in Phase 2 epilepsy trial

Ovid Therapeutics (NASDAQ:OVID) reported positive topline results from its Phase 2 study evaluating soticlestat in children with Dravet syndrome or Lennox-Gastaut syndrome, two highly refractory epilepsy syndromes...

August 25, 2020

Developments

Imara gets EC orphan drug designation for sickle cell disease

Imara’s (NASDAQ:IMRA) IMR-687 received European Commission orphan drug designation for the treatment of sickle cell disease. In a statement, Imara’s president and CEO, Rahul Ballal, said the designation reinforces “the...

August 25, 2020

Developments

Bristol Myers Squibb to acquire TIAP’s Forbius

Bristol Myers Squibb (NYSE:BMY) entered a definitive agreement to acquire closely-held Forbius, a clinical-stage protein engineering company that designs and develops biotherapeutics for the treatment of cancer and...

August 24, 2020

Markets

HCW cuts Onconova Therapeutics to neutral; removes PT

H.C. Wainwright downgraded Onconova Therapeutics (NASDAQ:ONTX) to “neutral” from “buy” without a price target after the company’s Phase 3 INSPIRE trial with rigosertib in high-risk myelodysplastic syndromesfailed on...

August 24, 2020

Developments

CohBar begins Phase 1b trial with CB4211 for NASH and obesity

CohBar (NASDAQ:CWBR) dosed first subjects with CB4211 in the Phase 1b stage of its Phase 1a/1b clinical trial for non-alcoholic steatohepatitis (NASH) and obesity. The Phase 1b study is designed to evaluate one dose...

August 24, 2020

Developments

Bionano Genomics acquires Lineagen to boost genetics diagnostics

Bionano Genomics (NASDAQ:BNGO) acquired closely-held Lineagen, a genetics diagnostic company, to further support its leadership in digital cytogenetics and comprehensive genetic diagnostics for pediatric...

August 24, 2020

Markets

Brookline starts 9 Meters Biopharma at buy; PT $5

Brookline Capital Markets initiated coverage of 9 Meters Biopharma (NASDAQ:NMTR) with a “buy” rating and $5 price target. At midday on Aug. 20, the stock was quoted at 68 cents. 9 Meters is focused on two...

August 20, 2020

Developments

Entera Bio reports interim data from Phase 2 osteoporosis trial

Entera Bio (NASDAQ:ENTX) reported interim results from its Phase 2 trial assessing EB613 for the treatment of osteoporosis. The trial has currently enrolled 131 postmenopausal female subjects with osteoporosis, or low...

August 20, 2020

Developments

Precision BioSciences gets FDA fast track designation for allogeneic CAR-T cell therapy

Precision BioSciences’ (NASDAQ:DTIL) allogeneic chimeric antigen receptor (CAR-T) cell therapy, PBCAR0191, received FDA fast track designation for the treatment of advanced B-cell precursor acute lymphoblastic leukemia...

August 20, 2020

Developments

Kazia gets FDA fast track designation for glioblastoma

Kazia Therapeutics’ (NASDAQ:KZIA) paxalisib received FDA fast track designation for the treatment of glioblastoma. Interim data from the company’s Phase 2 trial demonstrated overall survival of 17.7 months for patients...

August 20, 2020

Subscribe